Safe Use of Nivolumab in a Patient with Epipharyngeal Carcinoma and Preexisting Ulcerative Colitis: A Histologically Proven Case Report.
5-aminosalicylic acid (5-ASA)
anti-PD-1 antibody
immune-related adverse event (irAE)
nivolumab
ulcerative colitis
Journal
Internal medicine (Tokyo, Japan)
ISSN: 1349-7235
Titre abrégé: Intern Med
Pays: Japan
ID NLM: 9204241
Informations de publication
Date de publication:
15 Apr 2020
15 Apr 2020
Historique:
pubmed:
6
2
2020
medline:
2
10
2020
entrez:
4
2
2020
Statut:
ppublish
Résumé
Nivolumab, an antibody against human programmed cell death 1 (PD-1), enhances pre-existing immune responses and has antitumor activity. However, it may also cause undesirable immune-related adverse events (irAEs), such as anti-PD-1-related colitis. In addition, Nivolumab can worsen pre-existing autoimmune diseases. Ulcerative colitis (UC) is a chronic inflammatory disease of the colon. Its exact cause is unknown, but it may involve the dysregulation of the mucosal immune response. Thus, it is of great interest whether nivolumab can affect UC activity. This is the first report of a patient with epipharyngeal carcinoma and ulcerative colitis who was confirmed to have been safely treated with nivolumab based on autopsy findings.
Identifiants
pubmed: 32009094
doi: 10.2169/internalmedicine.3901-19
pmc: PMC7205527
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Nivolumab
31YO63LBSN
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1105-1109Références
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Hum Immunol. 2014 Mar;75(3):227-33
pubmed: 24374044
Aliment Pharmacol Ther. 1988 Feb;2(1):33-40
pubmed: 2979230
Ann Oncol. 2017 Feb 1;28(2):368-376
pubmed: 27687304
J Exp Med. 2005 Apr 18;201(8):1205-15
pubmed: 15824083
N Engl J Med. 2015 May 21;372(21):2018-28
pubmed: 25891174
Cancer Immunol Immunother. 2018 May;67(5):825-834
pubmed: 29487980
Am J Gastroenterol. 2010 Mar;105(3):501-23; quiz 524
pubmed: 20068560
Inflamm Bowel Dis. 2012 Aug;18(8):E1598-600
pubmed: 22069060
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
Clin Gastroenterol Hepatol. 2017 Sep;15(9):A35-A36
pubmed: 28351793
Histopathology. 2017 Mar;70(4):558-567
pubmed: 28000302
N Engl J Med. 2016 Nov 10;375(19):1856-1867
pubmed: 27718784
Am J Surg Pathol. 2017 May;41(5):643-654
pubmed: 28296676
Gastroenterology. 2005 Jun;128(7):1868-78
pubmed: 15940622
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Cancer Treat Rev. 2017 Jun;57:36-49
pubmed: 28550712
JAMA Oncol. 2016 Feb;2(2):234-40
pubmed: 26633184
N Engl J Med. 2017 Nov 9;377(19):1824-1835
pubmed: 28891423
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Cancer Immunol Res. 2014 Sep;2(9):846-56
pubmed: 24872026
Mol Immunol. 2013 Jun;54(2):173-80
pubmed: 23280396
J Crohns Colitis. 2013 Dec;7(12):982-1018
pubmed: 24184171
J Clin Oncol. 2010 Jul 1;28(19):3167-75
pubmed: 20516446
Transl Lung Cancer Res. 2015 Oct;4(5):560-75
pubmed: 26629425
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
BMC Gastroenterol. 2018 Aug 31;18(1):135
pubmed: 30170560